193 related articles for article (PubMed ID: 21317177)
1. The mucosal addressin cell adhesion molecule antibody PF-00547,659 in ulcerative colitis: a randomised study.
Vermeire S; Ghosh S; Panes J; Dahlerup JF; Luegering A; Sirotiakova J; Strauch U; Burgess G; Spanton J; Martin SW; Niezychowski W
Gut; 2011 Aug; 60(8):1068-75. PubMed ID: 21317177
[TBL] [Abstract][Full Text] [Related]
2. Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial.
Vermeire S; Sandborn WJ; Danese S; Hébuterne X; Salzberg BA; Klopocka M; Tarabar D; Vanasek T; Greguš M; Hellstern PA; Kim JS; Sparrow MP; Gorelick KJ; Hinz M; Ahmad A; Pradhan V; Hassan-Zahraee M; Clare R; Cataldi F; Reinisch W
Lancet; 2017 Jul; 390(10090):135-144. PubMed ID: 28527704
[TBL] [Abstract][Full Text] [Related]
3. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin.
Feagan BG; Greenberg GR; Wild G; Fedorak RN; Paré P; McDonald JW; Dubé R; Cohen A; Steinhart AH; Landau S; Aguzzi RA; Fox IH; Vandervoort MK
N Engl J Med; 2005 Jun; 352(24):2499-507. PubMed ID: 15958805
[TBL] [Abstract][Full Text] [Related]
4. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial.
Reinisch W; Sandborn WJ; Hommes DW; D'Haens G; Hanauer S; Schreiber S; Panaccione R; Fedorak RN; Tighe MB; Huang B; Kampman W; Lazar A; Thakkar R
Gut; 2011 Jun; 60(6):780-7. PubMed ID: 21209123
[TBL] [Abstract][Full Text] [Related]
5. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis.
Colombel JF; Rutgeerts P; Reinisch W; Esser D; Wang Y; Lang Y; Marano CW; Strauss R; Oddens BJ; Feagan BG; Hanauer SB; Lichtenstein GR; Present D; Sands BE; Sandborn WJ
Gastroenterology; 2011 Oct; 141(4):1194-201. PubMed ID: 21723220
[TBL] [Abstract][Full Text] [Related]
6. Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis.
Miele E; Pascarella F; Giannetti E; Quaglietta L; Baldassano RN; Staiano A
Am J Gastroenterol; 2009 Feb; 104(2):437-43. PubMed ID: 19174792
[TBL] [Abstract][Full Text] [Related]
7. Monoclonal antibodies specific for beta 7 integrin and mucosal addressin cell adhesion molecule-1 (MAdCAM-1) reduce inflammation in the colon of scid mice reconstituted with CD45RBhigh CD4+ T cells.
Picarella D; Hurlbut P; Rottman J; Shi X; Butcher E; Ringler DJ
J Immunol; 1997 Mar; 158(5):2099-106. PubMed ID: 9036954
[TBL] [Abstract][Full Text] [Related]
8. A review of infliximab use in ulcerative colitis.
Wilhelm SM; McKenney KA; Rivait KN; Kale-Pradhan PB
Clin Ther; 2008 Feb; 30(2):223-30. PubMed ID: 18343261
[TBL] [Abstract][Full Text] [Related]
9. Amelioration of murine experimental colitis by inhibition of mucosal addressin cell adhesion molecule-1.
Kato S; Hokari R; Matsuzaki K; Iwai A; Kawaguchi A; Nagao S; Miyahara T; Itoh K; Ishii H; Miura S
J Pharmacol Exp Ther; 2000 Oct; 295(1):183-9. PubMed ID: 10991977
[TBL] [Abstract][Full Text] [Related]
10. Treating ulcerative colitis by Adacolumn therapeutic leucocytapheresis: clinical efficacy and safety based on surveillance of 656 patients in 53 centres in Japan.
Hibi T; Sameshima Y; Sekiguchi Y; Hisatome Y; Maruyama F; Moriwaki K; Shima C; Saniabadi AR; Matsumoto T
Dig Liver Dis; 2009 Aug; 41(8):570-7. PubMed ID: 19211314
[TBL] [Abstract][Full Text] [Related]
11. A randomized, double-blind, sham-controlled study of granulocyte/monocyte apheresis for active ulcerative colitis.
Sands BE; Sandborn WJ; Feagan B; Löfberg R; Hibi T; Wang T; Gustofson LM; Wong CJ; Vandervoort MK; Hanauer S;
Gastroenterology; 2008 Aug; 135(2):400-9. PubMed ID: 18602921
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis.
Maini RN; Breedveld FC; Kalden JR; Smolen JS; Davis D; Macfarlane JD; Antoni C; Leeb B; Elliott MJ; Woody JN; Schaible TF; Feldmann M
Arthritis Rheum; 1998 Sep; 41(9):1552-63. PubMed ID: 9751087
[TBL] [Abstract][Full Text] [Related]
13. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis.
Lichtenstein GR; Kamm MA; Boddu P; Gubergrits N; Lyne A; Butler T; Lees K; Joseph RE; Sandborn WJ
Clin Gastroenterol Hepatol; 2007 Jan; 5(1):95-102. PubMed ID: 17234558
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
[TBL] [Abstract][Full Text] [Related]
15. Development and validation of receptor occupancy pharmacodynamic assays used in the clinical development of the monoclonal antibody vedolizumab.
Wyant T; Estevam J; Yang L; Rosario M
Cytometry B Clin Cytom; 2016 Mar; 90(2):168-76. PubMed ID: 25908521
[TBL] [Abstract][Full Text] [Related]
16. In patients with ulcerative colitis, adsorptive depletion of granulocytes and monocytes impacts mucosal level of neutrophils and clinically is most effective in steroid naïve patients.
Tanaka T; Okanobu H; Yoshimi S; Murakami E; Kogame A; Imagawa H; Numata Y; Kuga Y; Moriya T; Ohya T; Kajiyama G
Dig Liver Dis; 2008 Sep; 40(9):731-6. PubMed ID: 18387860
[TBL] [Abstract][Full Text] [Related]
17. Intravenous immunoglobulin therapy for active, extensive, and medically refractory idiopathic ulcerative or Crohn's colitis.
Levine DS; Fischer SH; Christie DL; Haggitt RC; Ochs HD
Am J Gastroenterol; 1992 Jan; 87(1):91-100. PubMed ID: 1728132
[TBL] [Abstract][Full Text] [Related]
18. Randomised clinical trial: a phase 1, dose-ranging study of the anti-matrix metalloproteinase-9 monoclonal antibody GS-5745 versus placebo for ulcerative colitis.
Sandborn WJ; Bhandari BR; Fogel R; Onken J; Yen E; Zhao X; Jiang Z; Ge D; Xin Y; Ye Z; French D; Silverman JA; Kanwar B; Subramanian GM; McHutchison JG; Lee SD; Shackelton LM; Pai RK; Levesque BG; Feagan BG
Aliment Pharmacol Ther; 2016 Jul; 44(2):157-69. PubMed ID: 27218676
[TBL] [Abstract][Full Text] [Related]
19. Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial.
Vermeire S; O'Byrne S; Keir M; Williams M; Lu TT; Mansfield JC; Lamb CA; Feagan BG; Panes J; Salas A; Baumgart DC; Schreiber S; Dotan I; Sandborn WJ; Tew GW; Luca D; Tang MT; Diehl L; Eastham-Anderson J; De Hertogh G; Perrier C; Egen JG; Kirby JA; van Assche G; Rutgeerts P
Lancet; 2014 Jul; 384(9940):309-18. PubMed ID: 24814090
[TBL] [Abstract][Full Text] [Related]
20. Natalizumab for active Crohn's disease.
Ghosh S; Goldin E; Gordon FH; Malchow HA; Rask-Madsen J; Rutgeerts P; Vyhnálek P; Zádorová Z; Palmer T; Donoghue S;
N Engl J Med; 2003 Jan; 348(1):24-32. PubMed ID: 12510039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
